[Changes in blood coagulation in treatment with ALL-BFM-90 and NHL-BFM-90 protocols].
1. Treatment according to the ALL/NHL-BFM 90 protocol I (induction phase) caused multiple and severe coagulation changes in all 14 patients of our study. Glucocorticoids alone made Fibrinogen drop to 148 mg/dl, AT III and Protein C rise to 136% or even 179% respectively. After day 12, immediately following the start of therapy with Coli-Asparaginase (ASP), fibrinogen continued to drop to reach its lowest average value of 46 mg/dl on day 24. Anticoagulant factors like plasminogen (lowest average value: 36%), AT III (47%) and Protein C (93%) dropped abruptly. These alterations were reversed after discontinuation of Glucocorticoids and ASP. During consolidation (protocol II) similar alterations are observed as in protocol I when Glucocorticoids are applied alone. However, after Erwinia-ASP there is no fall in AT III, plasminogen, and Protein C as is observed in protocol I with Coli-ASP. 2. Severe hemorrhages or thromboses are uncommon as compared to the degree of coagulation changes which can be regularly observed. Complications occur more often in girls. Most of them are seen during the 2nd or 3rd week of simultaneous ASP-Glucocorticoid therapy. 3. To avoid twofold alteration of hemostasis it should be considered to apply Glucocorticoids and ASP separately and to replace Coli-ASP by Erwinia-ASP. The efficacy of prophylactic replacement of decreased coagulation factors has not yet been confirmed. Immunologic and infectious side effects have to be taken into consideration. 4. More definite recommendations can be given when each suspected bleeding and/or thrombosis is confirmed by imaging procedures, when it is documented and registered, and when coagulation studies are performed during the critical phase.
Sutor
A H
AH
Universitäts-Kinderklinik Freiburg.
Niemeyer
C
C
Sauter
S
S
Witt
I
I
Kaufmehl
K
K
Rombach
A
A
Brandis
M
M
Riehm
H
H
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000990:Antithrombin III / Q000378:metabolism; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D001780:Blood Coagulation Tests; D002648:Child; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced*; D006801:Humans; D016399:Lymphoma, T-Cell / Q000097:blood / Q000188:drug therapy*; D008297:Male; D010958:Plasminogen / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011486:Protein C / Q000378:metabolism; D013927:Thrombosis / Q000097:blood / Q000139:chemically induced*; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D011486:Protein C; D014750:Vincristine; D000990:Antithrombin III; D005340:Fibrinogen; D010958:Plasminogen; D001215:Asparaginase; D011241:Prednisone; D003630:Daunorubicin
Gerinnungsveränderungen bei Behandlung mit den Protokollen ALL-BFM-90 und NHL-BFM-90.